RxDoctor Payments Data

Lukas Hockman, MD

Urology · Kansas City, MONPI 1891177226

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Urogen Pharma, Inc. at 38.7% of the total.

$13,612in general payments, 2019–2025

Across 138 payments — averaging $98.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$5K
  • Boston Scientific$3K
  • Profound Medical Corp.$2K
  • Histosonics, Inc.$560
  • Medtronic$454
  • Intuitive Surgical$259
  • plus $2K from 34 others

What the payments were for

  • Speaking & faculty fees$4,06330%
  • Travel & lodging$3,87228%
  • Food & beverage$5,57841%
  • Education$1001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,612 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$236,122
Medicare patients
456
Services billed
3,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron90$75,413
MyrbetriqMirabegron87$61,020
ElmironPentosan Polysulfate Sodium14$15,391
Tamsulosin Hcl417$5,402
Trospium Chloride ErTrospium Chloride18$4,709
Finasteride201$2,819
Estradiol32$2,207
Silodosin14$1,589
Methenamine Hippurate22$1,551
Cefdinir48$793
Potassium Citrate ErPotassium Citrate16$533
Dutasteride17$466
Alfuzosin Hcl ErAlfuzosin Hcl19$403
Oxybutynin Chloride ErOxybutynin Chloride21$307
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$133$75,41390 claims
Astellas Pharma US IncMyrbetriq$100$61,02087 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.

Other urology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →